Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,331
  • Shares Outstanding, K 21,440
  • Annual Sales, $ 36,430 K
  • Annual Income, $ -112,420 K
  • 36-Month Beta 3.83
  • Price/Sales 2.34
  • Price/Cash Flow N/A
  • Price/Book 0.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.71 +54.24%
on 11/16/17
4.50 -7.11%
on 12/08/17
+1.43 (+52.00%)
since 11/15/17
3-Month
1.91 +118.85%
on 09/22/17
4.50 -7.11%
on 12/08/17
+2.07 (+98.10%)
since 09/15/17
52-Week
1.15 +263.48%
on 08/29/17
4.50 -7.11%
on 12/08/17
+2.35 (+128.42%)
since 12/15/16

Most Recent Stories

More News
Aptevo Therapeutics' Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples

New APVO436 Preclinical Data Show Robust T-Cell Engagement and Cytotoxicity in AML Patient Specimens

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma

Anticipates 2 IND Filings in 2018 for Novel Bispecific Antibody Candidates

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Reports Third Quarter 2017 Financial Results

Strengthened Cash Position to Support Ongoing R&D and Commercial Activities;

APVO : 4.18 (+5.03%)
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised

Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.

APVO : 4.18 (+5.03%)
EBS : 46.80 (+1.10%)
GSK : 34.99 (-0.71%)
SNY : 43.17 (+0.19%)
Aptevo Therapeutics Presents New Preclinical Data on APVO436 - a Next Generation ADAPTIR(TM) Bispecific Antibody Candidate

New Preclinical Data Show APVO436 Demonstrates Rapid and Significant Reduction in Skeletal Tumor Burden in Mice with Well-Established and Disseminated Tumors

APVO : 4.18 (+5.03%)
Alligator Bioscience Aptevo Therapeutics: Tumor Antigen 5T4 Associated with Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527

LUND, Sweden and SEATTLE, Washington, October 24, 2017 /PRNewswire/ --

APVO : 4.18 (+5.03%)
Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 - a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics

ALG.APV-527 Engineered to Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting

New Autoimmune Candidate APVO210 Demonstrates Targeted Cytokine Delivery for Application in Various Autoimmune and Inflammatory Diseases

APVO : 4.18 (+5.03%)
Aptevo Therapeutics, Analyst Coverage, ADAPTIR Platform and Recent Drug Asset Sale

NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

APVO : 4.18 (+5.03%)
Biotech Sector is Fertile Ground for Continued Rally, New Drug Developments and Latest Collaborations

PALM BEACH, Florida, October 6, 2017 /PRNewswire/ --

TRPX : 5.26 (-1.87%)
WEED.TO : 19.52 (-0.05%)
APVO : 4.18 (+5.03%)
ZYNE : 11.47 (+0.44%)
SKVI : 0.0425 (-11.46%)
MNKD : 2.81 (-5.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

2nd Resistance Point 4.39
1st Resistance Point 4.29
Last Price 4.18
1st Support Level 4.04
2nd Support Level 3.89

See More

52-Week High 4.50
Last Price 4.18
Fibonacci 61.8% 3.22
Fibonacci 50% 2.83
Fibonacci 38.2% 2.43
52-Week Low 1.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.